Anti-GITR antibodies
View Patent ↗Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.
1. A binding compound that binds to human GITR comprising:
a) an antibody light chain variable domain, or antigen binding fragment thereof, having three CDR sequences selected from the group consisting of SEQ ID NOs: 56, 67, and 78; and
b) an antibody heavy chain variable domain, or antigen binding fragment thereof, having three CDR sequences selected from the group consisting of SEQ ID NOs: 23, 34, and 45.
2. A binding compound of claim 1 wherein:
a) the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 104; and
b) the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 105.
3. The binding compound of claim 2 , further comprising a heavy chain constant region comprising a γ1 human heavy chain constant region.
4. The binding compound of claim 2 , further comprising a heavy chain constant region comprising a γ4 human heavy chain constant region.
5. The binding compound of claim 2 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
6. A pharmaceutical composition comprising the antibody binding compound of claim 2 and a pharmaceutically acceptable carrier.